A Deeper Look into BTK Inhibitors in the
Management of B-Cell Malignancies: Individualizing Treatment for
Improved Clinical and Economic Outcomes
A continuing medical education activity sponsored by NAMCP and AAMCN.
Expert Perspectives on the Role of
BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): What Managed
Care Needs to Know for Improved Clinical and Economic Outcomes is a
3-part live webinar series that
will provide attendees with the latest information in the management
of CLL
This is Part 1 of the series focusing on individualizing treatment
for improved clinical and economic outcomes
This activity is an archive from the webinar held April 1, 2020
This activity is valid from May 1, 2020 to
May 1, 2022 |
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company and Janssen
Biotech, Inc.
Description:
Bruton's tyrosine kinase (BTK) is an enzyme that in humans is
encoded by the BTK gene. BTK is abundantly expressed and
constitutively active in the pathogenesis of B cell hematological
malignancies. Therefore, BTK is considered as an attractive target
for treatment of B-cell malignancies. These options, known as BTK
inhibitors, have changed the treatment paradigm in several different
B-cell malignancies in recent years. These agents differ in dosing,
efficacy, and toxicities, and as these options for B-cell
malignancies grow, it is essential to understand their clinical and
economic role in the treatment paradigm to offer patients the safest
and most efficacious treatment, while also controlling costs.
Upon completion of this
activity, participants will be able to:
-
Compare and contrast the BTK
inhibitors, including their pharmacological differences
-
Discuss key published clinical
trials, ongoing clinical trials, and guideline recommendations
for BTK inhibitors in B-Cell malignancies, with a focus on
chronic lymphocytic leukemia (CLL)
-
Formulate effective strategies for
ensuring the proper selection and use of BTK inhibitors in the
care of individual patients and patient populations
-
Identify patients with B-Cell
malignancies, with a focus on CLL, for whom a BTK inhibitor is
an appropriate choice for the next step in the management of
their cancer
Faculty: |
Richard R. Furman, MD
Morton Coleman, M.D. Distinguished Professor of Medicine
Weill Cornell Medicine |
Disclosure:
|
Dr. Furman
serves on ad advisory board for Abbvie, Acerta,
AstraZeneca, Beigene, Genentech, Janssen, Loxo Oncology,
Oncotracker, Pharmacyclics, Sunesis, TG Therapeutics,
and Verastem Oncology. He serves as a consultant for
Incyte. He has received grants/research support from
Abbvie, Astrazeneca, Sunesis, TG Therapeutics. His
presentation has been peer reviewed for any bias. |
|
Planning Committee:
Bill Williams,
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
to disclose.
Will Williams has no relevant financial relationships to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This presentation is supported by
educational grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company and Janssen
Biotech, Inc.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |